Serum procalcitonin in diagnosing prognosis of infective endocarditis

doi:10.3969/j.issn.1673-8640.2016.04.001

Abstract

Abstract:

Objective To analyze the significance of serum procalcitonin （PCT） for the prognosis of infective endocarditis（IE）. Methods A total of 80 patients with IE were enrolled. IE patients with poor prognosis （severe complications or death） were as poor prognosis group,and IE patients without complications were as no complication group. Serum PCT of the 2 groups were determined by enzyme-linked fluorescence analysis,and C-reactive protein（CRP） was analyzed by nephelometry immunoassay. The levels of PCT and CRP were compared between the 2 groups. The sensitivities, specificities,positive predictive values and negative predictive values of PCT and CRP for judging IE poor prognosis were compared. Results PCT and CRP in poor prognosis group had higher levels and positive rates than those in no complication group（P<0.05）. The sensitivity, specificity, positive predictive value and negative predictive value of PCT for IE poor prognosis diagnosis had no statistical significance compared with CRP （P>0.05）. Conclusions Monitoring serum PCT is of important significance for the prognosis diagnosis of IE,which should be combined with CRP determination when available.

Key words: Procalcitonin, C-reactive protein, Infective endocarditis

CLC Number:

R446.62

ZHANG Haixia, DU Gang, XU Haifeng, YANG Guiying, LIU Yajun, PENG Jing, YU Chong, PENG Qiongying. Serum procalcitonin in diagnosing prognosis of infective endocarditis[J]. Laboratory Medicine, 2016, 31(4): 243-246.

Figures/Tables 3

References 15

1	VERHAGEN DW,HERMANIDES J,KOREVAAR JC,et al.Prognostic value of serial C-reactive protein measurements in left-sided native valve endocarditis[J]. Arch Intern Med,2008,168(3):302-307.
2	HEIRO M,HELENIUS H,SUNDELL J,et al.Utility of serum C-reactive protein in assessing the outcome of infective endocarditis[J]. Eur Heart J,2005,26(18):1873-1881.
3	刘林华. 感染性心内膜炎20例诊治体会[J].中国当代医药,2012,19(8):186.
4	MARUNA P, NEDELNÍKOVÁ K, GÜRLICH R. Physiology and genetics of procalcitonin[J]. Physiol Res,2000,49(Supp l):S57-S61.
5	KARZAI W,OBERHOFFER M,MEIER-HELLMANN A,et al.Procalcitonin--a new indicator of the systemic response to severe infections[J].Infection,1997,25(6):329-334.
6	TANRIVERDI H,ÖRNEK T,ERBOY F,et al.Comparison of diagnostic values of procalcitonin,C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD[J]. Wien Klin Wochenschr,2015,127(19-20):756-763.
7	JEONG S,PARK Y,CHO Y,et al.Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture[J]. Clin Chim Acta,2012,413(21-22):1731-1736.
8	郎媛媛,沈永明,杨毅,等.降钙素原和C反应蛋白对儿童血流感染中血培养阳性标本的预测价值[J]. 国际检验医学杂志,2013,34(22):2967-2968.
9	JEREB M,KOTAR T,JURCA T,et al.Usefulness of procalcitonin for diagnosis of infective endocarditis[J]. Intern Emerg Med,2009,4(3):221-226.
10	OLAISON L,HOGEVIK H,ALESTIG K.Fever,C-reactive protein, and other acute-phase reactants during treatment of infective endocarditis[J]. Arch Intern Med,1997,157(8):885-892.
11	CORNELISSEN CG,FRECHEN DA,SCHREINER K,et al.Inflammatory parameters and prediction of prognosis in infective endocarditis[J]. BMC Infect Dis,2013,13:272.
12	ELBEY MA,KALKAN ME,AKDAG S,et al.Predictors of mortality in patients with prosthetic valve infective endocarditis:a nation-wide multicenter study[J]. Cardiol J,2013,20(3):323-328.
13	OKADA Y,HOSONO M,SASAKI Y,et al.Preoperative increasing C-reactive protein affects the outcome for active infective endocarditis[J]. Ann Thorac Cardiovasc Surg,2014,20(1):48-54.
14	KNUDSEN JB,FUURSTED K,PETERSEN E,et al.Procalcitonin in 759 patients clinically suspected of infective endocarditis[J]. Am J Med,2010,123(12):1121-1127.
15	MÜLLER B,HARBARTH S,STOLZ D,et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia[J]. BMC Infect Dis,2007,7:10.

组别	例数	PCT（ng/mL）	CRP（mg/L）
IE不良预后组	43	4.01±3.69^*	65.1±4.6^*
IE无并发症组	37	0.64±0.58	42.5±13.6

组别	例数	PCT（ng/mL）	CRP（mg/L）
IE不良预后组	43	4.01±3.69^*	65.1±4.6^*
IE无并发症组	37	0.64±0.58	42.5±13.6

组别	例数	PCT		CRP
组别	例数	阳性	阴性	阳性	阴性
IE不良预后组	43	32（74.4）	11（25.6）	31（72.1）	12（27.9）
IE无并发症组	37	11（29.7）	26（70.3）	13（31.1）	24（64.9）
χ²值		15.977		10.975
P值		< 0.05		< 0.05

组别	例数	PCT		CRP
组别	例数	阳性	阴性	阳性	阴性
IE不良预后组	43	32（74.4）	11（25.6）	31（72.1）	12（27.9）
IE无并发症组	37	11（29.7）	26（70.3）	13（31.1）	24（64.9）
χ²值		15.977		10.975
P值		< 0.05		< 0.05

指标	敏感性	特异性	阳性预测值	阴性预测值
PCT	74.4（32/43）	70.3（26/37）	74.4（32/43）	70.3（26/37）
CRP	72.1（31/43）	64.9（24/37）	70.5（31/44）	66.7（24/36）